Sanofi's Bleeding-Disorder Treatments Get Approval in China
By Aimee Look
Sanofi said two bleeding disorder treatments for both chronic and acute conditions have been approved in China, expanding its hematology offerings in the country.
The French pharmaceutical company said Thursday that China approved two medicines, Qfitlia and Cablivi, bringing Sanofi's approvals this year in China to five.
Qfitlia is an antithrombin-lowering therapy for people with hemophilia, which works to rebalance the body's blood-clotting process. Its approval comes after data from late-stage studies showed that it had meaningful bleed protection for hemophilia patients, Sanofi said.
Meanwhile, Cablivi addresses a rare blood clotting disorder, acquired or immune-mediated thrombotic thrombocytopenic purpura, Sanofi said.
"These approvals mark another step in Sanofi's long-term commitment to China," the company said.
Earlier this year, it reached approval for Tzield for stage 2 type 1 diabetes, and Sarclisa for multiple myeloma in China.
Write to Aimee Look at aimee.look@wsj.com
(END) Dow Jones Newswires
December 11, 2025 01:42 ET (06:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
This Once-Hot AI Stock Now Looks Deeply Undervalued
The 10 Best Companies to Invest in Now
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
United States